Sanofi India Limited has announced its financial performance for the quarter ended March 31, 2026. The company reported a revenue of ₹4,723 million and a profit of ₹1,026 million. Key highlights include exceptional double-digit growth in the insulin portfolio, driven by the diabetes injectable segment. Despite transitional impacts, the company maintains a solid foundation through strategic partnerships in cardiovascular and central nervous system therapies.
Financial Performance Overview
For the quarter ending March 31, 2026, Sanofi India Limited reported a steady financial performance. The company achieved a revenue from operations of ₹4,723 million, compared to ₹4,198 million in the previous quarter. The profit for the period stood at ₹1,026 million, reflecting the company’s ability to navigate market transitions and maintain operational efficiency.
Strategic Growth in Diabetes Care
The company’s insulin portfolio has emerged as a significant growth driver, recording double-digit growth for the second consecutive quarter. Managing Director Deepak Arora noted that insulin remains a gold standard for comprehensive diabetes care, validated by 14% growth compared to the previous quarter and 19% year-on-year growth. This strong performance reinforces the company’s established equity within the diabetes injectable segment.
Leadership and Governance Changes
The company also announced significant leadership transitions effective April 30, 2026. Following the completion of the tenure of Mr. Aditya Narayan and Mrs. Usha Thorat as Independent Directors, the board has appointed Mr. Rahul Bhatnagar as the new Chairman of the Board. Additionally, the company has reconstituted its key board committees, including the Audit, Nomination and Remuneration, Stakeholders Relationship, Risk Management, and Corporate Social Responsibility committees to ensure robust governance moving forward.
Source: BSE
